SEC Form 4 · accession 0001179110-19-001054
ACCELERON PHARMA INC · XLRN
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Robert K Zeldin
Officer — EVP & Chief Medical Officer
Period of report
Jan 25, 2019
Accepted (ET)
Jan 29, 2019 · 5:40 pm EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001280600
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common Stock | Jan 25, 2019 | A | 2,200 | $0.00 | A | 19,103 | D |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Option to Purchase Common StockF1 | $41.64 | Jan 25, 2019 | A | 13,000 | A | — | Jan 25, 2029 | Common Stock | 13,000 | 13,000 | D |
Explanation of responses
- F1The shares of common stock underlying this stock option award vest in equal quarterly installments over the four years after January 1, 2019.